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events or overall mortality in the general
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Abstract
Background: To investigate the impact of uric acid (UA) levels on cardiovascular disease and mortality at a
population level.
Methods: Prospective analysis of baseline serum UA measurement and 15 year follow-up data from the Busselton
Health Survey (n = 4,173), stratified by existence or absence of baseline cardiovascular disease. Outcomes were
ascertained from state-wide hospital discharge and mortality registries. Cox regression produced adjusted hazard
ratios (HR) for UA level as continuous and categorical (low, medium, high) predictor for cardiovascular events (CVE)
and mortality. Gout was defined as a patient’s self-reported history of gout.
Results: After age and gender adjustment each 0.1 mmol/L rise in UA level was associated with increased mortality
(HR 1.19, CI 1.04–1.36), cardiovascular mortality (HR 1.27, CI 1.03–1.57) and first CVE (HR 1.28, CI 1.13–1.44) in
participants with no history of CVE. Adjustment for behavioural and biomedical risk factors of cardiovascular disease
attenuated these associations. Results for participants with a history of CVE and for a subset of 1,632 participants
using UA levels (2–6 measurements) averaged over time were similar. The overall prevalence of hyperuricemia was
10.7%. When stratified by history of gout, UA level was significantly associated with increased risk of cardiovascular
mortality only in participants with a history of CVE (HR 2.13, CI 1.03–4.43).
Conclusions: Despite the considerable prevalence of hyperuricemia in 10.7% of the population, single or time
averaged measures of UA were not independently predictive of incident cardiovascular disease or mortality.
Hyperuricemia did associate with an increased risk of cardiovascular death only in participants with gout and
existing cardiovascular disease.
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Background
Hyperuricemia is an increasingly prevalent metabolic
condition that develops when inherited or acquired con-
ditions decrease the ability of the kidneys to secrete uric
acid [1]. Unique to humans who have become incapable
of breaking down uric acid (UA), hyperuricemia leads to
widespread uric acid deposition in a variety of tissues.
Typically, the first clinical presentation of hyperuricemia
is the development of gouty arthritis, in which the build-
up of monosodium urate (MSU) crystals causes an acti-
vation of the NLRP3 inflammasome response releasing
IL-1β and IL-18 in an attempt to attract macrophages to
remove the birefringent crystals [2]. If left untreated,
crystal deposition can occur in multiple joints, and gen-
erates a significant inflammatory response. Experimental
studies shows that MSU crystals also can deposit in
blood vessels walls including coronary arteries where
they can induce endothelial dysfunction, oxidative stress,
inflammation and platelet activation [3–9]. Hyperuricemia
has been associated with arterial hypertension, stroke and
heart disease [10–12], but the clinical significance of hy-
peruricemia as a risk factor for vascular events remains
unresolved, leading to ambiguity regarding the need to
treat asymptomatic hyperuricemia [9, 13–25].
The Busselton Health Survey (BHS) was designed to
examine the longitudinal relationship between health
measures and outcomes in a well described Western
Australian population cohort [26, 27]. The aim of the
current analysis was to investigate whether increased
baseline and time averaged UA levels alone or together
with a history of gout were risk factors for cardiovascu-
lar events and mortality in the adult BHS cohort.
Methods
Baseline measurements and follow-up outcome events
Details of the 1994/95 BHS have been described previously
[27]. Survey participants completed a comprehensive ques-
tionnaire underwent various measurements and a fasting
blood sample collection. Smoking history, alcohol con-
sumption, diet, minutes of moderate and vigorous intensity
leisure time physical activity per usual week, diabetes and
medications were obtained by questionnaire. Physical activ-
ity was calculated as (minutes/week of moderate intensity
activities) + 2 × (minutes/week of vigorous intensity activ-
ity). Alcohol consumption was labelled ‘light’ if consump-
tion was ≤140 g/week and ‘heavy’ if >140 g/week. The
composite diet score ranged from 0 to 8, representing the
number of healthier diet choices [26]. Body mass index
was defined as weight (kg) divided by height (m) squared.
Blood pressure was measured using a mercury sphygmo-
manometer after five minutes rest in a sitting position.
Blood tests for this analysis include serum total and HDL
cholesterol, triglycerides, C-reactive protein (CRP), creatin-
ine and UA level (by uricase-based spectrophotometry).
Renal function was derived from creatinine level, using the
MDRD estimated glomerular filtration rate (eGFR) for-
mula. Gout status was defined as self-report of a physician
diagnosis of gout.
About half of the participants (1,632) had attended
additional surveys before the 1994/95 survey at which
serum UA had been assessed. To overcome potential
bias from changes in serum UA measurement methods
across the multiple surveys we converted the UA values
at each survey to Z-scores using the age group and sex
specific means and standard deviations for all people in
those cross-sectional surveys (each survey had about
4000 participants). For this sub-cohort of 1994/1994 sur-
vey participants with multiple UA measurements (range
2–6) we calculated the average UA Z-score across all
their measures as well as the average annual change in
their UA Z-score, as determined from a linear regression
of their multiple UA Z-scores on calendar year of survey.
Outcome events during the 15 year follow-up period
to 2010 were ascertained from death records and the
WA Hospital Morbidity Collection which records all
hospital separations in public and private hospitals in
WA. International Classification of Diseases, 9th revision
(ICD-9-CM) codes were used for events up to 30 June
1999, and ICD-10-AM codes for subsequent events. Three
outcome events were analysed. Time to death from any
cause, time to death from cardiovascular diseases (ICD-9
390–459; ICD-10 I00-99 G45), and time to first fatal or
non-fatal cardiovascular event defined as a hospital admis-
sion with a principal discharge diagnosis of coronary heart
disease (ICD-9 410–414; ICD-10 I20–25) stroke (ICD-9
430–437; ICD-10 I60–68 G45), congestive heart failure
(ICD-9 428; ICD-10 I50) peripheral arterial disease (ICD-9
440–448; ICD-10 I70–79) or death from cardiovascular
disease. A baseline history of cardiovascular events (CVE)
was defined as having any hospital admission for non-
fatal, cardiovascular diseases (ICD-9 & ICD-9-CM
390–459) during the 15 years before the survey (i.e.
1980 to 1994). Diabetes was based on self-reported
doctor–diagnosed diabetes or on diabetes treatment
(tablets/insulin) at the survey or a history of hospital
admissions (ICD-9 250). The Human Research Ethics
Committee of the Department of Health of WA ap-
proved the BHS and WA-HMDC record linkage [28].
Statistical analysis
Variables with skewed distributions were log trans-
formed for use in regression models. Cox regression
models for time from 1994/95 survey to first outcome
event were used to obtain adjusted hazard ratios for UA
level considered both as a continuous variable (in mmol/L
and Z-score) and also as a categorical variable (low
medium and high). The cut-off levels for low, medium
and high (hyperuricemic) UA levels were based on current
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normal reference ranges defined by the local pathology
laboratory (see footnote to Table 1). Two levels of ad-
justment were used: Model 1 was adjusted for age (as
quadratic) and sex and Model 2 was further adjusted
for potential confounders. The list of behavioural and
biomedical cardiovascular risk factors considered as po-
tential confounders is shown in Table 1. The variables
that were at least modestly associated (i.e. p < 0.10) with
serum UA and with the CVE event outcome (after ad-
justment for age and sex) were considered as potential
confounders in Model 2 and included smoking status,
BMI, SBP, hypertension medications, total cholesterol,
HDL cholesterol, In(triglycerides), lipid medications,
diuretic use, In(CRP) and eGFR. An extension of Model
2 that included the self-reported history of gout and an
interaction between history of gout and UA level was
used to determine whether the effect of UA on CVE
and mortality outcomes differed in people with and
without a history of gout. Results from Cox regression
models are presented as estimated hazard ratios (with
95% confidence interval and p-value) and p-values < 0.05
are considered as significant evidence of an effect. Results
are presented for the full cohort and also for the sub-
cohort with multiple measures of UA. The proportional
hazards assumption for UA in relation to outcomes was
tested using an interaction between UA and follow-up
time and was found to hold. All analyses were performed
using SAS 9.4 software (SAS Institute Inc).
Results
We included 3,475 participants free of CVE and 698
participants with a history of CVE at baseline. The over-
all risk factor profile is typical of community samples at
that time (Table 1) even though baseline age and preva-
lence of CVD risk factors were higher in the group with
a history of CVE. Mean (SD) UA level was 0.31 mmol/L
(0.08) with hyperuricemia observed in 9% in the group
free of CVE vs. 16.5% in those with known CVE. During
fifteen years of follow-up, 461 (13%) of the group free of
CVE experienced a first CVE event and 408 (12%) par-
ticipants of this group died; CVE accounted for approxi-
mately one third of fatalities (myocardial infarction 28
other CHD 35, congestive heart failure 10, stroke 38,
peripheral vascular disease 12, and other CVE 32). Mortal-
ity, CVE death and CVE recurrence rates were roughly
three times higher in those with a history of CVE at
baseline.
Table 2 shows estimates for the association between
baseline UA levels and CVE and mortality in participants
free of CVE at baseline. There is a significant association
between UA level and all three outcomes in Model 1 (age
and sex adjusted). After further adjustment for potential
confounders these associations are attenuated and no lon-
ger significant (Model 2). In the group with known CVE,
there was again a significant association between UA and
cardiovascular mortality and cardiovascular events but not
Table 1 Characteristics of the full cohort by history of CVE at
baseline
Characteristic or measure CVE history = no
(n = 3,475)
CVE history = yes
(n = 698)
Male gender (%) 44.3 44.7
Age (years) 47.8 (16.2) 62.1 (14.5)
Smoking
Never (%) 53.6 49.4
Ex (%) 32.1 43.4
Current (%) 14.3 7.2
Alcohol
Never (%) 6.8 7.2
Ex (%) 7.9 14.6
Light (%) 61.3 55.9
Mod/Heavy/Unknown (%) 24.1 22.3
Physical activity (mins/week) 275 (363) 206 (306)
Diet score (range 0 to 8) 3.15 (1.51) 3.35 (1.51)
BMI (kg/m2) 25.9 (4.1) 26.6 (4.1)
Systolic BP (mm Hg) 122 (17) 131 (21)
Diastolic BP (mm Hg) 74 (10) 76 (11)
Hypertension meds (%) 11.3 44.4
Cholesterol (mmol/L) 5.50 (1.09) 5.82 (1.09)
HDL (mmol/L) 1.40 (0.38) 1.37 (0.43)
Triglycerides (mmol/L) 1.24 (0.81) 1.54 (1.22)
Lipid meds (%) 1.5 8.0
Diabetes (%) 4.7 11.5
Gout history (%) 1.4 3.6
Diuretic use (%) 3.0 11.7
CRP (mg/L) 2.97 (7.73) 3.86 (10.21)
MDRD eGFR (mL/min/1.73 m2) 72.3 (13.1) 63.5 (14.4)
UA (mmol/L) 0.3108 (0.0806) 0.3353 (0.0921)
UA z-score −0.0345 (0.9722) 0.1173 (1.0649)
UA categorya
Low (%) 39.6 35.2
Medium (%) 51.1 48.3
High (%) 9.4 16.5
Outcomes
Follow-up time (years) 15.4 (2.6) 13.6 (4.4)
Deaths 408 (11.7) 244 (35.0)
CVE deaths 155 (4.5) 118 (16.9)
CVE events 461 (13.3) 301 (43.1)
Table shows mean (SD), percent or N (%)
aLow (UA ≤ 0.30 in subjects ≥ 46 years, ≤ 0.24 in women < 46 years) Medium
(0.30 < UA ≤ 0.42 in subjects ≥ 46 years, 0.24 < UA ≤ 0.36 in women < 46 years)
High (UA > 0.42 in subjects ≥ 46 years, UA > 0.36 in women < 46 years)
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all-cause mortality in Model 1, but associations were no
longer significant in Model 2 (Additional file 1: Table S1).
Multiple UA measurements (range 2–6) were available
for a sub-cohort of 2,139 participants whose characteris-
tics did not differ significantly from the full cohort. In this
sub-cohort, the average annual change in UA Z-score was
0.0007 per year in those free of CVE and 0.0076 per year
in those with known CVE at baseline. For participants free
of CVE at baseline, the association between the average
UA Z-score and outcomes was very similar to the associa-
tions seen for the single UA Z-score in Model 1 and all as-
sociations again attenuated in Model 2 (Table 3). The
findings in participants with known CVE and multiple UA
measurements were also similar to results using one UA
measurement (Additional file 1: Table S2).
Given the loss of predictive value of UA levels after we
adjusted for a large number of confounders in Model 2
we fitted two intermediate models that were the same as
Model 2 but which did not adjust for CRP (Model 2A)
or did not adjust for SBP/use of antihypertensive drugs
(Model 2B). In those free of CVE at baseline, the inter-
mediate model without CRP adjustment (Model 2A in
Additional file 1: Table S3) gave similar UA effects to the
fully adjusted Model 2, indicating that adjustment for
CRP was not responsible for the attenuated UA effect in
Model 2. However, the intermediate model that was not
adjusted for SBP/antihypertensive drugs (Model 2B in
Additional file 1:Table S3) showed similar UA effects to
Model 1 indicating that blood pressure was responsible
for the attenuated UA effect in Model 2. The results
from the intermediate models for the cohort with known
CVE at baseline (Additional file 1: Table S4) indicated
that in this sub-group neither adjustment for CRP
(Model 2A) and/or SBP & anti-hypertensive medications
(Model 2B) were responsible for attenuation of the UA
effect, compared to the fully adjusted Model 2.
A history of gout was a marginally significant predictor
of all-cause mortality in participants with known CVE in
a fully adjusted Model 2 (HR 1.65 CI 0.99–2.77) (Table 4).
To determine if the effect of UA differed in those with and
without a history of gout, we included an interaction be-
tween UA and a history of gout in Model 2 and found that
the effect of UA on all outcomes was greater in those with
a history of gout, but only reached significance for cardio-
vascular mortality in the group with known CVE (HR 2.13
vs 0.94, p = 0.038) (Table 5).
Discussion
In this prospective study of a well described population
in Western Australia the overall prevalence of hyperuri-
cemia was 10.7% which associated with an increased age
and gender adjusted risk for incident cardiovascular
events and mortality. However adjustments for behav-
ioural and biomedical cardiovascular risk factors com-
pletely tempered this effect, except in the subgroup of
participants with a history of gout and baseline CVE. The
use of time averaged UA levels provided no additional
prognostic information.
Our data confirm the complexity of the interactions
between UA and the traditional CVE risk factors. The
increased CVE risk associated with hyperuricemia (HR
1.52 CI 1.13–2.04, p = 0.005) in patients free of CVE at
baseline after adjustment for the two most powerful risk
factors (age and gender), became non-significant with
further adjustment for a range of cardiovascular risk fac-
tors (HR 1.03, CI 0.73–1.44, p = 0.88). A similar loss of
predictive value due to interactions with known risk fac-
tors was observed in one of the largest population stud-
ies on uric acid (the Framingham Heart study), where
mean age at inclusion (47 years) was similar and which
also fully adjusted for CVE risk factors [29]. The effect
sizes of UA in this study are comparable and in agree-
ment with findings from a large meta-analysis on the
Table 2 Association between UA level and all-cause mortality,
CVE mortality and CVE event in the full cohort without a history
of CVE at baseline
UA measure Model 1a Model 2a
HR (95% CI) p-value HR (95% CI) p-value
All-cause mortality
UAb 1.19 (1.04,1.36) 0.010 1.15 (0.98,1.35) 0.089
UA z-scoreb 1.15 (1.03,1.27) 0.009 1.12 (0.99,1.27) 0.069
UA category 0.210 0.666
Low 1.00 1.00
Medium 1.07 (0.86,1.33) 0.553 1.01 (0.79,1.28) 0.939
High 1.31 (0.97,1.79) 0.080 1.15 (0.81,1.65) 0.428
Cardiovascular mortality
UAb 1.27 (1.03,1.57) 0.025 1.17 (0.91,1.52) 0.225
UA z-scoreb 1.21 (1.02,1.43) 0.025 1.14 (0.93,1.40) 0.212
UA category 0.539 0.974
Low 1.00 1.00
Medium 1.16 (0.81,1.67) 0.411 0.99 (0.67,1.47) 0.964
High 1.30 (0.79,2.15) 0.295 1.05 (0.58,1.90) 0.872
Cardiovascular event
UAb 1.28 (1.13,1.44) <0.001 1.09 (0.94,1.26) 0.267
UA z-scoreb 1.19 (1.08,1.31) <0.001 1.05 (0.94,1.18) 0.377
UA category 0.016 0.985
Low 1.00 1.00
Medium 1.23 (1.00,1.52) 0.049 1.02 (0.81,1.28) 0.877
High 1.52 (1.13,2.04) 0.005 1.03 (0.73,1.44) 0.883
Table shows hazard ratio, 95% CI and p-value from Cox regression models
aModel 1 is adjusted for sex and age (and age squared). Model 2 is further
adjusted for smoking status, BMI, SBP, hypertension meds, cholesterol, HDL
cholesterol, ln(triglycerides), lipid meds, diuretic use, ln(CRP) and eGFR
bHR is presented for a change of 0.1 mmol/L for UA and for a change of 1.0
for UA Z-score
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Table 3 Association between UA level and all-cause mortality, CVE mortality and CVE event in the subcohort with multiple UA
measures and without history of CVE at baseline
UA measure Model 1a Model 2a
HR (95% CI) p-value HR (95% CI) p-value
All-cause mortality
UAb 1.17 (1.01,1.36) 0.031 1.17 (0.98,1.40) 0.082
UA z-scoreb 1.13 (1.00,1.27) 0.040 1.13 (0.98,1.30) 0.097
UA category 0.636 0.906
Low 1.00 1.00
Medium 1.07 (0.83,1.36) 0.609 1.03 (0.79,1.34) 0.833
High 1.18 (0.84,1.67) 0.343 1.09 (0.73,1.64) 0.658
Average UA z-scoreb 1.18 (1.02,1.36) 0.027 1.18 (1.00,1.39) 0.046
Annual change UA z-scorec 1.14 (0.92,1.41) 0.220 1.11 (0.88,1.39) 0.379
Cardiovascular mortality
UAb 1.18 (0.94,1.49) 0.152 1.10 (0.83,1.47) 0.507
UA z-scoreb 1.14 (0.94,1.37) 0.173 1.07 (0.85,1.35) 0.544
UA category 0.838 0.977
Low 1.00 1.00
Medium 1.11 (0.75,1.63) 0.603 0.96 (0.63,1.46) 0.841
High 1.15 (0.66,2.00) 0.622 0.98 (0.51,1.89) 0.962
Average UA z-scoreb 1.18 (0.93,1.49) 0.172 1.15 (0.88,1.49) 0.303
Annual change UA z-scorec 1.21 (0.89,1.64) 0.219 1.10 (0.79,1.54) 0.573
Cardiovascular event
UAb 1.25 (1.09,1.44) 0.001 1.09 (0.92,1.30) 0.300
UA z-scoreb 1.17 (1.05,1.31) 0.004 1.05 (0.92,1.20) 0.446
UA category 0.032 0.848
Low 1.00 1.00
Medium 1.28 (1.01,1.63) 0.042 1.08 (0.83,1.40) 0.576
High 1.52 (1.08,2.14) 0.015 1.09 (0.73,1.62) 0.668
Average UA z-scoreb 1.15 (1.00,1.31) 0.053 1.03 (0.88,1.20) 0.746
Annual change UA z-scorec 1.31 (1.05,1.64) 0.017 1.11 (0.88,1.41) 0.384
Table shows hazard ratio, 95% CI and p-value from Cox regression models
aModel 1 is adjusted for sex and age (and age squared). Model 2 is further adjusted for smoking status, BMI, SBP, hypertension meds, cholesterol, HDL cholesterol,
ln(triglycerides), lipid meds, diuretic use, ln(CRP) and eGFR
bHR is presented for a change of 0.1 mmol/L for UA and for a change of 1.0 for UA Z-score and average UA z-score
cHR is presented for a change of 0.1 for annual change in UA Z-score. HR comes from model that also includes average UA z-score
Table 4 Hazard ratios (95% CI) for effect of history of gout on outcomes in Model 2 in the full cohort
CVE history = no CVE history = yes
HRa (95% CI) p-value HRa (95% CI) p-value
All-cause mortality 0.99 (0.61,1.60) 0.960 1.65 (0.99,2.77) 0.055
Cardiovascular mortality 0.79 (0.36,1.72) 0.553 1.34 (0.63,2.88) 0.447
Cardiovascular event 0.83 (0.48,1.42) 0.492 0.95 (0.56,1.63) 0.863
aHR is adjusted for sex, age (and age squared), smoking status, BMI, SBP, hypertension meds, cholesterol, HDL cholesterol, ln(triglycerides), lipid meds, diuretic use,
ln(CRP) and eGFR
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relation between UA levels and coronary heart disease
where the unadjusted HR of 1.34 decreased to a moderate
1.07 after full adjustment for traditional risk factors [19].
Even in studies where UA was found to predictive of sub-
types of CVE, the effect sizes were modest at best [13].
While hyperuricemia cannot be considered a fully inde-
pendent risk factor for cardiovascular morbidity or mor-
tality in healthy persons, it may still deserve consideration
as a risk indicator in the evaluation and possibly manage-
ment of the metabolic syndrome [13, 30, 31].
Given the notable consistency by which UA can induce
CVE risk factors such as hypertension in experimental
models [7] we further investigated if certain covariates
could be responsible for rendering UA a non-significant
predictor. Using intermediate models, that were based on
published associations between CVE risk factors and UA,
we found that in participants free of CVE at baseline, the
effect of UA on future CVE development was lost after ad-
justment for hypertension. As UA can activate the renin-
angiotensin system and is an independent predictor of
hypertension incidence and progression in community-
based cohorts, this suggests that over time hyperuricemia
becomes superseded by hypertension as a main risk factor.
This is further supported by findings that a lowering of
blood pressure occurs when using uric acid lowering ther-
apies alone [7, 32]. In contrast, in participants with exist-
ing CVE, neither the adjustment for CRP or hypertension
influenced the UA effect on cardiovascular mortality or
other study endpoints. The lack of effect between UA and
CRP in patients with established CVE is in opposition with
the theory and data that suggest that UA can induce ex-
pression of CRP in vascular endothelial and smooth
muscle cells [33, 34], where CRP as a marker of low grade
vessel inflammation is the important risk factor [35]. It is
possible that the results from the intermediate models
could be explained by the uric acid paradox theory, i.e.
that the role of UA in vascular pathophysiology varies over
time and the balance may shift from beneficial (antioxi-
dant) effects of UA towards more pro-atherogenic effects
[13, 36–38].
UA levels may fluctuate over time under the influence
of both exo- and endogenous factors and higher time av-
eraged UA levels have previously been found to associate
with metabolic syndrome [39]. This is one of the first
studies to investigate the influence of both the average
and change in UA levels over time as a predictor for
CVE. While the time averaged UA Z-scores produced
more robust hazard ratios in age and gender adjusted
models this improved strength was again lost after full
adjustment in Model 2. This endorses single measure-
ments instead of averaged UA levels over time in CVE
prediction [40].
Hyperuricemia is associated with incident gout in a
dose-dependent manner [20, 31, 41]. The prevalence of
self-reported doctor diagnosed gout in this population
cohort (1.4% in participants free of CVE and to 3.6% in
participants with known CVE) fall within the range of
published self- and doctor reported gout prevalence
rates and confirm its standing as the commonest form
of inflammatory joint disease [12, 42–44]. The develop-
ment of gout is a signal that a critical threshold for uric
acid loading has been crossed [45] and the recent intro-
duction of dual energy CT scanning for visualisation and
quantification of total body uric acid load could prove to
be a powerful tool for delineating this critical threshold
[46]. Furthermore, in participants with a history of gout
and CVE at baseline an increase of 0.1 mmol/L in UA
was independently associated with a more than two-fold
increase in risk of cardiovascular mortality. This is in
line with several studies showing that gout is a more re-
liable predictor for CVE and associated mortality than
hyperuricemia [11, 21, 22, 31, 41, 45, 47, 48].
Prolonged hyperuricemia or gout increases CVD burden
and atherosclerotic plaque development [49] particularly
Table 5 Adjusted hazard ratios (and 95% CI) for an increase of 0.1 mmol/L in uric acid overall and by history of gout in the full
cohort from an extended Model 2 that includes interaction between history of gout and uric acid level


















































HR is adjusted for sex, age (and age squared), smoking status, BMI, SBP, hypertension meds, cholesterol, HDL cholesterol, ln(triglycerides), lipid meds, diuretic use,
ln(CRP) and eGFR
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in those with renal impairment [50]. The potential
mechanism for the increased risk of serious CVD events,
i.e. increased vulnerability of atherosclerotic plaque to rup-
turing, could be explained by the increase in inflammation
about UA crystal deposition in the endothelium, where
macrophage activation about the plaque site causes a rup-
ture of the plaque cap in a process similar to cholesterol
crystal deposits [2, 51]. Uric acid lowering therapy is there-
fore likely to have its largest potential to prevent CVE in
this particular sub-group.
The prevalence of hyperuricemia in this Western Aus-
tralian population cohort was considerably lower than
the 19% prevalence reported for the same study period
in the US based NHANES III study as the prevalence of
hyperuricemia has since further risen in the US and was
found to be 16% in South Australia between 2008 and
2010 it is more than likely that the WA prevalence has
since risen as well [47, 52, 53].
The limitations of this study require consideration.
The lower age in participants free of CVE at baseline (as
reflected by the low rate of subsequent CVE and death)
may have led to an underestimation of the longer term
effect of hyperuricemia despite age adjustments. As par-
ticipants were predominantly of European descent our
results cannot be generalised to cohorts with a different
ethnic background. Also, the model for the effect of UA
on outcomes in people with a history of gout is based on
relatively low numbers and should thus be interpreted
with caution. Finally, a history of gout was self-reported
and we were unable to ascertain the use of uric acid low-
ering drugs. While we corrected for known risk factors
for CVD new methods have been proposed, e.g. Mendelian
Randomisation to identify further risk factors (alleles) that
contribute to disease process and outcomes in rheumatic
diseases [54]. However, we did not have genetic variables
available for this cohort. The strengths of this study lie in
the long-term prospective follow-up of a large population
cohort, the comprehensive baseline data in the complete
cohort allowing full adjustment for CVD risk factors.
The baseline stratification by the presence of a CV event
avoided the cited potential for left-censorship bias in other
studies [13]. The validation provided by using multiple
uric acid measurements adds to the reliability of our data.
Conclusions
Despite a significant prevalence in the Western Australian
community, there was no attributable cardiovascular risk
associated with hyperuricemia in asymptomatic individ-
uals. Our data do suggest that the cardiovascular impact
of hyperuricemia varies across the stages of CVE devel-
opment. Thus, UA lowering therapy for CVE preven-
tion is not warranted in asymptomatic individuals with
hyperuricemia, but may benefit patients with gout who
have existing CVE.
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